enGene Holdings Inc. (NASDAQ:ENGN) Stake Lessened by Omega Fund Management LLC

Omega Fund Management LLC decreased its holdings in enGene Holdings Inc. (NASDAQ:ENGN - Free Report) by 51.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 526,357 shares of the company's stock after selling 550,000 shares during the period. enGene comprises approximately 2.9% of Omega Fund Management LLC's investment portfolio, making the stock its 7th biggest holding. Omega Fund Management LLC owned about 1.19% of enGene worth $3,500,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of ENGN. Deep Track Capital LP grew its holdings in enGene by 74.8% in the fourth quarter. Deep Track Capital LP now owns 4,557,575 shares of the company's stock worth $30,308,000 after purchasing an additional 1,949,942 shares during the last quarter. Fcpm Iii Services B.V. grew its holdings in enGene by 11.0% in the fourth quarter. Fcpm Iii Services B.V. now owns 9,632,561 shares of the company's stock worth $64,057,000 after purchasing an additional 954,610 shares during the last quarter. Franklin Resources Inc. grew its holdings in enGene by 48.7% in the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company's stock worth $7,854,000 after purchasing an additional 389,918 shares during the last quarter. Blue Owl Capital Holdings LP grew its holdings in enGene by 3.3% in the fourth quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company's stock worth $21,014,000 after purchasing an additional 101,006 shares during the last quarter. Finally, Corton Capital Inc. purchased a new position in enGene in the fourth quarter worth $157,000. Institutional investors own 64.16% of the company's stock.

enGene Stock Performance

NASDAQ:ENGN traded up $0.05 during mid-day trading on Friday, hitting $3.45. The company's stock had a trading volume of 89,406 shares, compared to its average volume of 131,764. enGene Holdings Inc. has a 1 year low of $2.65 and a 1 year high of $13.28. The company has a debt-to-equity ratio of 0.08, a current ratio of 16.87 and a quick ratio of 16.87. The stock has a market cap of $175.87 million, a price-to-earnings ratio of -5.95 and a beta of -0.36. The business's fifty day moving average is $4.18 and its two-hundred day moving average is $6.08.

Analyst Ratings Changes

Several equities analysts have issued reports on ENGN shares. Piper Sandler started coverage on shares of enGene in a report on Tuesday, February 18th. They issued an "overweight" rating and a $26.00 price target on the stock. Morgan Stanley dropped their price objective on shares of enGene from $37.00 to $34.00 and set an "overweight" rating on the stock in a report on Tuesday, March 11th. JMP Securities reissued a "market outperform" rating and set a $18.00 price objective on shares of enGene in a report on Tuesday, April 29th. HC Wainwright reissued a "buy" rating and set a $25.00 price objective on shares of enGene in a report on Tuesday, March 11th. Finally, UBS Group lowered shares of enGene from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $34.00 to $7.00 in a report on Friday, February 14th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $23.29.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.